MedTrace Logo

A Study of Isoquercetin in People With Ovarian Cancer

NCT07303894 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

Conditions

Interventions

DRUG

Isoquercetin

Cohort B and Cohort C will take isoquercetin

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Zwicker, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2032-01-31
Completion
2032-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07303894 on ClinicalTrials.gov